InnoCore Pharmaceuticals’ Post

#China’s #BiopharmaIndustry Faces a Crucial Test! Novo Nordisk’s #diabetes-turned-#weightloss drug #Ozempic dominates the Chinese market with a remarkable 77% share, but its future in China hangs in the balance due to a high-stakes patent battle. Reportedly, China’s #GLP1 drug market is projected to reach $11.4 billion by 2033, driven by rapid innovation and a surge in local competitors. The outcome of #NovoNordisk’s #patent dispute will be a crucial test for how China supports domestic innovation while safeguarding international patents. 📊 GlobalData Plc Insights: Rachel Cheung from The Wire China quotes GlobalData Plc that Eli Lilly and Company’s #Mazdutide is expected to bring in $75 million from global sales outside China by 2030, highlighting the intense competition and market opportunities in this burgeoning sector. As China’s biopharma landscape shifts, the spotlight is on how international giants and local players will navigate this evolving market. Reach out to GlobalData #Pharma analyst team for more insights. #Decodethefuture with GlobalData Plc GlobalData Healthcare Prashant Khadayate Geetha Nelluri Srija Chilamula #ChinaMarket #HealthcareReform #PharmaceuticalIndustry #Innovation #PatentBattle #EliLilly

The establishment of a HK-FDA had been the talk of town for a while now, but still little detail is known. HKBIO recognizes its potential role in the regional biotech ecosystem and had been hosting a series of seminars surround the topic. Tomorrow's panel, titled 'Hong Kong Centre for Medical Products Regulation' will be the last in the series. I highly encourage anyone interested in healthcare developments in the region to dial in. But if you missed it, don't worry -- the upcoming biotech convention #BIOHK2024 on Sep 11-14 will shine a major spotlight on this topic! #hkfda #hkcmpr #biotech #hkbio #biohk #conference #convention #regulatory #pharmaceuticals #medicaldevices #tcm

Please visit to connect and discuss the latest trends in pharmacometrics!

Interesting Insights into International Engagement of Regulators at this FDA- EMA-Health Canada joint session. The key Topics discussed were: - FDA-EMA Parallel Scientific Advice Pilot Program for Complex Generics/ Hybrid Products - Generic Drug Cluster - International Collaboration Among Regulatory Agencies Enclosed is the link to the PowerPoints from.this session: https://lnkd.in/ggkdSXyK

Biosimilars LatAm - Europe 2024 Online Forum: Meet the Chairman Thomas Kirchlechner! Watch his video invitation and join us for this exciting event! This unique forum will bring together leading experts from Latin America and Europe to discuss the opportunities and challenges in the #biosimilars market. Key Highlights: - COFEPRIS's new Regulatory Certainty Strategy for Mexico. - Strategies from Latin American regulatory authorities to enhance collaboration with European manufacturers. - Brazil's successful model for Partnerships for Productive Development. - Institutional initiatives for biologics production in Colombia. 📅 Dates: June 19th, 20th, and 21st 🕒 Time: Mornings in Latin America and Afternoons in Europe 📍 Format: Online Advance your knowledge and engage with industry leaders! Register now and be part of this pivotal discussion! https://lnkd.in/gizVMKtb 💰 Request your exclusive discount code now and secure your spot at this unmissable forum Organized by JackLeckerman #BiosimilarsLatAm #Europe2024 #Pharmaceuticals #LatinAmerica #Europe #HealthcareInnovation #Biotech

Vicore sells rights to IPF drug in Japan; Roche to lay off 340 workers; Sensorion’s €50M offering >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #biotech #pharma #healthcare

Vicore sells rights to IPF drug in Japan; Roche to lay off 340 workers; Sensorion’s €50M offering >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #pharmaceutical #biotech

💊 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤 𝐁𝐮𝐢𝐥𝐝𝐬 $𝟐𝟐𝟎𝐌 𝐑𝐚𝐰 𝐈𝐧𝐠𝐫𝐞𝐝𝐢𝐞𝐧𝐭𝐬 𝐏𝐥𝐚𝐧𝐭 𝐢𝐧 𝐃𝐞𝐧𝐦𝐚𝐫𝐤! 🌟 𝐈𝐧 𝐀𝐮𝐠𝐮𝐬𝐭 𝟐𝟎𝟐𝟒, Novo Nordisk Pharmatech A/S, a unit that specializes in #producing drug ingredients, is spending 𝟏.𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 Danish kroner ($220 million) to build a plant in Køge, Denmark, that will make #rawmaterials. Even as supplies of Novo Nordisk’s immensely popular GLP-1 drugs Ozempic and Wegovywire start to #stabilize, the Danish drugmaker continues to announce #manufacturing and #capacity upgrades at a rapid clip. The 8,000-square-meter roughly 86,000-square-foot facility will include production, storage, office and laboratory space, Pharmatech said, adding that the outlay marks the biggest investment in its 75-year history. 𝐋𝐨𝐨𝐤 𝐚𝐭 𝐨𝐮𝐫 𝐂𝐨𝐫𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭 👉: https://bit.ly/4dPD2Vw #PharmaInvestment #Denmark #RawIngredients #PharmaInnovation #Pharmaceuticals #IndustryGrowth #DenmarkInvestment #Sustainability #prophecymarketinsights

Navigating the emerging biopharma market in the JAPAC region? Our latest article underscores the importance of understanding safety and regulatory requirements for successful drug development. This is particularly crucial for emerging biopharmas. Dive into the unique regulatory nuances in countries like Japan and China, with Dr Jayawant Fuke and Hye Jin Choi. Read more: https://bit.ly/49QQje7 #JAPAC #Biopharma #RegulatoryCompliance #DrugDevelopment

Thoughts on this? >> US-China tensions threaten to ensnare additional Chinese biopharma contractors >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #productmarketing #healthcare